Chardan Capital Reaffirms Buy Rating for iBio (NYSE:IBIO)

iBio (NYSE:IBIO)‘s stock had its “buy” rating reissued by Chardan Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $5.00 target price on the stock. Chardan Capital’s price objective indicates a potential upside of 488.24% from the company’s current price.

Separately, StockNews.com raised iBio to a “sell” rating in a research note on Tuesday, March 18th.

iBio Price Performance

Shares of IBIO opened at $0.85 on Monday. The firm has a 50 day simple moving average of $3.04 and a two-hundred day simple moving average of $2.90. iBio has a one year low of $0.64 and a one year high of $6.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.76 and a current ratio of 1.76.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iBio stock. Iridian Asset Management LLC CT bought a new position in iBio, Inc. (NYSE:IBIO) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 58,205 shares of the company’s stock, valued at approximately $234,000. Iridian Asset Management LLC CT owned approximately 0.59% of iBio as of its most recent SEC filing. 7.90% of the stock is currently owned by institutional investors.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.